FDA Approves Opdivo Combination for Unresectable or Metastatic Urothelial Carcinoma
The FDA approved nivolumab (Opdivo, Bristol Myers Squibb) in combination with cisplatin and gemcitabine for first-line treatment of adult patients with unresectable or metastatic urothelial carcinoma (UC).